trial · primary record
Clazakizumab
Kidney Failure, Chronic
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 20 |
| Primary completion | 2025-08-30 |
| Primary endpoint | Number of Treatment Related Adverse Effects of Clazakizumab Therapy (18 Month Period) |
| Registry ID | NCT03380962 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:40:32.468Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03380962
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.